Rezolute, Inc.

Stocks

RZLT

US76200L3096

Market Closed - Nasdaq Other stock markets 23:00:00 07/08/2026 +03			5-day change	1st Jan Change
4.690 ^USD	-0.21%		-0.64%	+98.73%

06-17	Rezolute, Inc. Highlights Results from Natural History Outcomes Studies and Its Ersodetug Clinical Program in Hyperinsulinism At Annual Meeting of the Endocrine Society	CI
06-03	Wedbush Adjusts Price Target on Rezolute to $6 From $5, Maintains Outperform Rating	MT

Transcript : Rezolute, Inc. - Special Call

Published on 12/11/2025 at 10:05 pm +03

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the sunRIZE Topline Data Conference Call. [Operator Instructions] Please note, this event is being recorded.

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Full unlimited browsing across the entire site

Access to all the news and all the data

Access to US, EUROPE AND ASIA Portfolios

Zero Ads for a completely uninterrupted reading experience

Pro Tools: Expert insights, Expert Screeners, historical financial data and reports, thematic lists, transcripts...

Latest news about Rezolute, Inc.

06-17	Rezolute, Inc. Highlights Results from Natural History Outcomes Studies and Its Ersodetug Clinical Program in Hyperinsulinism At Annual Meeting of the Endocrine Society	CI
06-03	Wedbush Adjusts Price Target on Rezolute to $6 From $5, Maintains Outperform Rating	MT
06-02	Rezolute Shares Rise After Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial	MT
06-02	Rezolute, Inc. Provides Positive Interim Data For Its Phase 3 UpLIFT Study Of Ersodetug In Tumor Hyperinsulinism	CI
06-02	Rezolute Says 6 Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial	MT
05-12	Rezolute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
05-01	Rezolute Inc Announces Oral Presentation Of Results From Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism	CI
03-25	Wedbush Upgrades Rezolute to Outperform From Neutral, Raises Price Target to $5 From $2	MT
03-24	Rezolute Shares Rise After US FDA Encourages Data Submission for Congenital Hyperinsulinism Program	MT
03-24	Rezolute Inc Provides Update on Congenital Hyperinsulinism Program Following Fda Meeting	CI
03-24	Rezolute Says It Had Encouraging FDA Meeting on Congenital Hyperinsulinism Drug Despite Missed Endpoint	DJ
03-24	Rezolute Says US FDA Encourages Data Submission for Congenital Hyperinsulinism Program	MT
03-23	Rezolute, Inc.(NasdaqCM:RZLT) dropped from S&P Biotechnology Select Industry Index	CI
02-13	Rezolute, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025	CI
01-08	Wedbush Doubles Price Target on Rezolute to $2 From $1, Keeps Neutral Rating	MT